strong cer top line ep growth
guidanc reiter alway go easiest comp
partial quarter us advair gener easi comp shingrix tesaro
dilut minor charg howev top saw one-
gain associ appar bolu sale ventolin possibl
advair us authoris gener posit phase
saw expect spillov effect respiratori drug price
breo appar price per rx would see appar
current stall nbrx
gener advair better-than-expect
perform gsk ceo state declin line
expect gsk remain confid keep hiv franchis
least stabl global recent investor survey cs us
survey saw good accept dual approach amongst physician
remain surpris continu us strength tivicay
gsk import catalyst credibl push
oncolog test pivot data bcma zejula howev
dont see current pipelin big enough refresh base busi
see fund constraint group look separ enlarg
consum unit within year gsk score mid pack global peer
recent analysi exposur us rebat reform
public dostarlimab endometri cancer
valuat gsk trade pe premium eu major
peer ex-azn pharmavalu ev/npv vs peer
make minor adjust estim
valuat metric
price-to-earnings rel local market
number share
price month
price rel chart measur perform
ftse share close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
glaxosmithklin plc gsk global healthcar group
engag creation discoveri develop manufactur
market pharmaceut product includ vaccin
medicin health-rel consum product
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
analysi show impact pipelin success
stronger forecast growth respiratori franchis
uncertainti impact us advair gener viiv
uncertainti level competit new drug gener
grey analysi show impact full pipelin failur
weaker forecast growth respiratori franchis
uncertainti impact us advair gener viiv
uncertainti level competit new drug gener
price rel chart measur perform ftse share
close
spot exchang rate
chang forecast
made minim chang forecast
figur chang forecast
pharma
pharma
pharma
chang lc ep growth
us advair stg
impact fx
impact fx
assum get close
prior guidanc
sale end
slight declin get
close level
sale end
breo sale
us
maintain
indian asset dispos
half increas cost
 half sg
margin
boost
line
expect
reach
 ifr
lower back
pfizer
feb rate sale
less op
nestl consum
prostat
gsk result commentari
pharma driven new respiratori nucala ellipta
nucala trelegi shingrix contribut strong growth
hiv good uptak juluca far
consum jv track close leadership announc
first pilot rtff malaria vaccin malawi
oper profit cer adjust strong shingrix perform ag
ep cer adjust
cash-flow gener weight half year
weak gbp result sale adjust ep
declin eu due price eros
devato key contribut wont properli kick end year
posit impact launch trelegi nucala juluca off-set declin older
brand establish product
success author gener provid boost advair well ventolin
howev overal advair outlook remain
return growth
tesaro dilut sustain impact
shingrix demand still strong us
growth mening vaccin
posit impact hepat cdc stockpil
headwind cervarix china compar infanrix pediatr competit
mid singl digit outlook driven shingrix sale
phase low margin contract manufactur
improv perform driven market respons
smaller divest phase
op profit improv typic higher margin due allergi
horlick unilev end year
adjust oper profit net incom
free cash flow
mileston payment novarti
gener cashflow expect weight
adjust ep
improv work capit cash manag underli cash gener
alloc resourc pipelin focu product launch
integr tesaro complet consum jv dispos nutrit busi
trelegi china approval/launch focu japan launch strategi
commerci execut see encourag sign nbrx equal
zejula parp ovarian market share stabl approv countri hong
kong franc spain next target submit china
prima data ovarian
shingrix capac expans track drive strong sale
demand remain strong us receiv first complet
dose seri
cer dtg contribut
slower growth previou qs due larger base continu competit
juluca pick use sinc data
grow prescrib confid drug regimen
futur growth come juluca devato
price cut franc spain itali one-off claw back releas triumeq impact
rescu year goe
cer good contribut japan brazil
target broader patient popul on-going studi
gemini data avail summer
tango salsa data file us
studi reduc inject per year
track expect file
 caus delay timelin bcma mm
mono remain track slight delay driven discuss
fda modifi protocol dose increas number patient due
 guidanc suggest margin degrad upsid
signific chang guidanc continu invest pipelin tesaro still
see impact advair gener still inventori adjust vaccin
year progress keep post guidanc
 new cfo first impress cost structur
initi observ number restructur see earli indic
around product priorit effect cost control program
improv effici strong focu improv margin organ across everi
line
 prescript gener advair show capac constraint happen
market
still earli day comment suppli chang outlook advair
 price pressur hiv post formulari exclus
strong stabl coverag portfolio formulari real signific
chang payer tri activ mang formulari guidelin overal
stabl optimist dovato coverag
 quantifi shingrix one portfolio
ad margin
 consensu model tivicay triumeq flat scrip trend show stiff
competit gilead
comment consensu hiv competit switch
margin overal run script stabl see growth
juluca dovato cabo cannib tivicay triumeq
em
 comment biolog asthma trend
establish clear posit start see benefit dupi take
bulk share xolair expans beyond us well share japan
work efficaci mechan nucala auto-injector provid anoth dose
option expect approv
data end year concern file bcma-adc multipl
mechan observ signific immun respons
synergist previou trial work well learn data
base mechan pre-clin data believ risk worth take
 thought long-term guidanc given
focus build progress set
composit busi chang consum jv impact tesaro
also impact pharma dispos
 excit vaccin pipelin
remov two non-prior asset univers flu vaccin stop post interim
remain commit flu pneumococc vaccin also stop prioriti
three rsv vaccin develop pead matern older adult believ
gsk first market fast track matern older vaccin also priorit
therapeut copd vaccin could prevent exacerb rate
 ambit china beyond consum
remain posit china concentr portfolio china seratid
major opportun cervarix third patient vaccin hpv look
approv shingrix work acceler pipelin product start lower base
high opportun
 seen step due gener advair affect dividend cover
strong focu wc manag last year good cash flow manag
lower profit year given advair gener step
restrict impact guidanc dividend re-affirmed term think
capit alloc unilev deal improv balanc sheet capac support pipelin
distribut sharehold bd larg focus digest deal
realiz valu excit close consum deal confid deliv
three year separ deal
 eu sale hiv play
hiv eu volum grew strongli dtg grew juluca start well franc
govern mandat price cut franc impact quarter
one compar itali overal pleas perform germani
like us seen switch competit everywher
 convers could get
reiter focu wc manag
 potenti impact new technolog product
provid updat focu gsk driven aim
molecul becom medicin increas believ human genet
reduct cost number patient sign sequenc function genom
machin learn ai help see never identifi target
could help product
profit tax underli gsk cs
profit tax underli gsk
profit tax report
average share
ep gsk fd
increment ep delay us gener advair
compani mention price
